SCHEMBL22246649

SCHEMBL22246649

CCCCc1ccc(NC(=O)c2ccsn2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.61
RAB9A P51151 6/20 0.61
LMNA P02545 1/20 0.61
SMN1; SMN2 Q16637 2/20 0.60
ALDH1A1 P00352 2/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
TRPV1 Q8NER1 2/20 0.53
POLB P06746 1/20 0.52
TP53 P04637 1/20 0.52
GAA P10253 1/20 0.52
KDM4E B2RXH2 2/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 2/20 0.50
GALR3 O60755 1/20 0.50
STING1 Q86WV6 1/20 0.49
MEN1 O00255 1/20 0.48
CASP3 P42574 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15014120 0.77 NPC1 (0.72) NPC1RAB9ALMNASMN1; SMN2ALDH1A1
SCHEMBL13210620 0.76 NPC1 (0.67) NPC1RAB9ALMNASMN1; SMN2ALDH1A1
SCHEMBL13515550 0.75 NPC1 (0.53) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1
SCHEMBL2915657 0.75 TRPV1 (0.72) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1
SCHEMBL2019464 0.74 POLB (0.70) NPC1RAB9ASMN1; SMN2ALDH1A1TRPV1
SCHEMBL15094124 0.74 CA12 (0.74) NPC1RAB9ASMN1; SMN2ALDH1A1TRPV1
SCHEMBL31277872 0.73 NPC1 (0.63) NPC1RAB9ALMNASMN1; SMN2ALDH1A1
SCHEMBL31277665 0.73 NPC1 (0.63) NPC1RAB9ALMNASMN1; SMN2ALDH1A1
SCHEMBL2748237 0.73 POLB (0.73) NPC1RAB9ASMN1; SMN2ALDH1A1TRPV1
SCHEMBL27644948 0.73 POLB (0.68) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230106899-A1 METHODS OF TREATING CANCER NOVARTIS PHARMA AG (CH) 2023-04-06 US disclosed
WO-2020150417-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2020-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230106899-A1 METHODS OF TREATING CANCER STING1, CGAS, TBK1 NPC1 249/4885RAB9A 1457/4885LMNA 1575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.